COPD is one of the top 10 leading cause of death in the U.S., the CDC says.

Connect Biopharma Holdings Limited CNTB recently shared positive topline results from its global Phase 2 study. The ...

Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –– Rademikibart ...

On Wednesday, Connect Biopharma Holdings Limited ( CNTB) reported positive preliminary topline results from its global Phase 2 Seabreeze STAT COPD study evaluating rademikibart as an add-on treatment ...

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced ...

AstraZeneca's experimental drug, tozorakimab, significantly reduces COPD exacerbations, as presented at the European ...

The Biologics License Application for tozorakimab 300mg, administered once every four weeks, has been accepted for Priority Review by the US Food and Drug Administration as an add-on maintenance ...

Landmark Joint Declaration launches against a backdrop of 480 million people affected by COPD and persistent gaps in ...

Connect Biopharma Holdings Limited announced topline results from its global Phase 2 study evaluating rademikibart, the Company?s next-generation, potentially best-in-class anti-interleukin-4-receptor ...

Add Yahoo as a preferred source to see more of our stories on Google. A new drug appeared to show promise in reducing rates of chronic obstructive pulmonary disease (COPD) symptoms in former and ...